Keynote Speakers

Robert Bazemore
President and Chief Executive Officer

Robert (Rob) Bazemore has served as President and Chief Executive Officer since September 2015. Prior to joining Epizyme, Rob served as Chief Operating Officer of Synageva, where he established the company's global commercial and medical organization to support the first product launch, and helped lead the broader transition to a sustainable commercial enterprise, through its acquisition in July 2015. With more than 25 years of experience across the life sciences industry, Rob held several senior leadership positions at Johnson & Johnson. This included his role as President of Janssen Biotech, where he led the successful launches of numerous products and indications, including the U.S. launches of the oncology therapies ZYTIGA® and IMBRUVICA®, as well as guiding the company's worldwide immunology portfolio strategy. Prior to Johnson & Johnson, he worked at Merck & Co., Inc. for 11 years in roles of increasing responsibility, including the launch of SINGULAIR® in the U.S.

Rob received a B.S. in Biochemistry from the University of Georgia. He currently sits on the Board of Directors of Ardelyx, Inc.

Andre Turenne
President and CEO
Voyager Therapeutics

Andre Turenne brings to Voyager extensive strategic business development and commercial leadership experience, including nearly 12 years at Genzyme and Sanofi. He most recently served as Sanofi's senior vice president, global head, business development and licensing, where he was responsible for partnering activities across all of Sanofi's business units, including Sanofi Pasteur, Sanofi Genzyme, Diabetes-Cardiovascular, General Medicines and Consumer Health, and also served as Chair of the Sanofi Transaction Committee. He previously served as global head of strategy and business development at Genzyme following its acquisition by Sanofi. In addition to his extensive business development transactions and leadership positions, Mr. Turenne has held senior leadership positions at the country level as general manager of Sanofi Genzyme Australia/New Zealand with P&L responsibility for that region and at the global franchise level as head of commercial operations for the Renal and Endocrinology division, which achieved one billion dollars in annual revenues during his time. Mr. Turenne began his career in industry as a consultant at Kendall Strategies, the consulting arm of Feinstein Kean Healthcare, now part of Ogilvy.

Mr. Turenne holds a B.A. from Kalamazoo College and an M.B.A. from the Tuck School of Business at Dartmouth.